Canada - TSX Venture Exchange - TSX-V:VPT - CA92281P2008 - Common Stock
The current stock price of VPT.CA is 0.12 CAD. In the past year, price increased by 20%.
ChartMill assigns a technical rating of 6 / 10 to VPT.CA. When comparing the yearly performance of all stocks, VPT.CA turns out to be only a medium performer in the overall market: it outperformed 61.01% of all stocks.
ChartMill assigns a fundamental rating of 1 / 10 to VPT.CA. Both the profitability and financial health of VPT.CA have multiple concerns.
Over the last trailing twelve months VPT.CA reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS increased by 23.15% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -1076.66% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
VentriPoint Diagnostics Ltd. is a medical device company, which engages in the development and commercialization of diagnostic tools that monitor patients with heart disease. The company is headquartered in Toronto, Ontario. The company went IPO on 2005-11-09. The company is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. The company develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. The company provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. The company has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.
VENTRIPOINT DIAGNOSTICS LTD
18 Hook Ave, Unit 101
TORONTO ONTARIO M2N 5Y7 CA
CEO: George Adams
Employees: 0
Phone: 14168484156
VentriPoint Diagnostics Ltd. is a medical device company, which engages in the development and commercialization of diagnostic tools that monitor patients with heart disease. The company is headquartered in Toronto, Ontario. The company went IPO on 2005-11-09. The company is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. The company develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. The company provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. The company has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.
The current stock price of VPT.CA is 0.12 CAD. The price decreased by -4% in the last trading session.
VPT.CA does not pay a dividend.
VPT.CA has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
VENTRIPOINT DIAGNOSTICS LTD (VPT.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.02).